Lantern Pharma Stock Fundamentals
| LTRN Stock | USD 3.80 0.06 1.60% |
Lantern Pharma fundamentals help investors to digest information that contributes to Lantern Pharma's financial success or failures. It also enables traders to predict the movement of Lantern Stock. The fundamental analysis module provides a way to measure Lantern Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lantern Pharma stock.
Lantern |
Lantern Pharma Company Return On Asset Analysis
Lantern Pharma's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Lantern Pharma Return On Asset | -0.34 |
Most of Lantern Pharma's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lantern Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Lantern Pharma has a Return On Asset of -0.3394. This is 96.12% lower than that of the Biotechnology sector and 98.56% lower than that of the Health Care industry. The return on asset for all United States stocks is 142.43% higher than that of the company.
Lantern Pharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Lantern Pharma's current stock value. Our valuation model uses many indicators to compare Lantern Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lantern Pharma competition to find correlations between indicators driving Lantern Pharma's intrinsic value. More Info.Lantern Pharma is currently regarded as number one stock in return on equity category among its peers. It is rated second overall in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lantern Pharma's earnings, one of the primary drivers of an investment's value.Lantern Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lantern Pharma's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lantern Pharma could also be used in its relative valuation, which is a method of valuing Lantern Pharma by comparing valuation metrics of similar companies.Lantern Pharma is currently under evaluation in return on asset category among its peers.
Lantern Fundamentals
| Return On Equity | -0.53 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | 12.57 M | ||||
| Shares Outstanding | 10.78 M | ||||
| Shares Owned By Insiders | 14.71 % | ||||
| Shares Owned By Institutions | 23.33 % | ||||
| Number Of Shares Shorted | 222.16 K | ||||
| Price To Book | 1.52 X | ||||
| EBITDA | (15.79 M) | ||||
| Net Income | (15.96 M) | ||||
| Cash And Equivalents | 62.15 M | ||||
| Cash Per Share | 5.74 X | ||||
| Total Debt | 234.47 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 12.38 X | ||||
| Book Value Per Share | 2.47 X | ||||
| Cash Flow From Operations | (14.35 M) | ||||
| Short Ratio | 3.27 X | ||||
| Earnings Per Share | (1.78) X | ||||
| Target Price | 20.5 | ||||
| Number Of Employees | 21 | ||||
| Beta | 1.63 | ||||
| Market Capitalization | 40.33 M | ||||
| Total Asset | 43.65 M | ||||
| Retained Earnings | (55.24 M) | ||||
| Working Capital | 40.66 M | ||||
| Net Asset | 43.65 M |
About Lantern Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lantern Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lantern Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lantern Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. The company was incorporated in 2013 and is headquartered in Dallas, Texas. Lantern Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.
When determining whether Lantern Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lantern Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lantern Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lantern Pharma Stock: Check out Lantern Pharma Piotroski F Score and Lantern Pharma Altman Z Score analysis. To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.